Coley Pharmaceuticals Group completes $60 million second round.

Investee Company – Coley Pharmaceutical Group

Investee Company Country – US/Germany

Investee Company Business Type – Drug Discovery

Type of Financing – Expansion – second funding round

Equity Providers – DWS Investment, DVG (advised by AP Asset Management), Commerzbank Private Equity, Bayview 2000, Global Life Science Partners, Techno Venture Management, QIAGEN, Alpinvest Holding (NIB Capital), Alafi Capital.

Equity Leader (Individual) – None Named.

Debt Providers – No debt financing.

Debt Type – N/A

Debt Leader (Individual) – N/A

Equity Amount – $60 million

Total Deal Value – $60 million

Other Advisors – AP Asset Management

Comments – Since the first round of financing in August 1999 Coley has expanded its management team, and improved its research capabilities. The first round of financing for $12.9million was led by TVM Techno Venture Management of Munich, Germany, as well as Alafi Capital Co., QIAGEN NV, Alpinvest Holding NV, Kredietbank S.A. Luxembourgeoise, and Mulligan Beteiligungs GmbH. As a result of the latest financing round Andreas Bremer, managing director of AP Asset Managment, has joined the board of directors at Coley.